Topotecan for Advanced Breast and Lung Cancer
Author Information
Author(s): PN Mainwaring, MC Nicolson, T Hickish, R Penson, S Joel, M Slevin, IE Smith
Primary Institution: Royal Marsden NHS Trust; St Bartholomew's Hospital
Hypothesis
Infusional topotecan might have superior activity to conventional schedules.
Conclusion
Infusional topotecan does not appear to offer a clinical advantage over conventional 5-day schedules against advanced NSCLC and advanced breast cancer.
Supporting Evidence
- Three patients achieved a partial response: one with NSCLC and two with advanced breast cancer.
- The major toxicities were neutropenia and thrombocytopenia.
- Median duration of survival was 41 weeks for NSCLC patients and 52 weeks for breast cancer patients.
Takeaway
Doctors tested a new way to give a cancer medicine called topotecan, but it didn't work better than the old way.
Methodology
Two open, phase II studies evaluated the activity and toxicity of infusional topotecan in patients with advanced NSCLC and advanced breast cancer.
Limitations
The study was terminated early due to lack of evidence supporting the hypothesis of increased activity for infusional topotecan.
Participant Demographics
{"total":25,"NSCLC":{"male":10,"female":2,"age_range":"39-65 years","median_age":46},"breast_cancer":{"male":0,"female":13,"age_range":"40-73 years","median_age":50}}
Statistical Information
Confidence Interval
{"NSCLC":"95% CI 0-39%","breast_cancer":"95% CI 2-45%"}
Want to read the original?
Access the complete publication on the publisher's website